Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.65 |
| ▸ | DDB1 | Q16531 | 9/20 | 0.65 |
| ▸ | STAT3 | P40763 | 2/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SNCA | P37840 | 1/20 | 0.50 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.49 |
| ▸ | CCNK | O75909 | 1/20 | 0.49 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17873757 | 0.94 | CRBN (0.69) | CRBNDDB1STAT3BRD4HDAC1 | |
| SCHEMBL17884379 | 0.92 | CRBN (0.66) | CRBNDDB1STAT3BRD4HDAC1 | |
| Trifluoroacetic Acid SCHEMBL17839625 | 0.90 | CRBN (0.68) | CRBNDDB1STAT3BRD4HDAC1 | |
| SCHEMBL18449107 | 0.90 | CRBN (0.72) | CRBNDDB1STAT3BRD4HDAC1 | |
| SCHEMBL23884257 | 0.89 | CRBN (0.66) | CRBNDDB1STAT3BRD4HDAC1 | |
| SCHEMBL24391022 | 0.88 | CRBN (0.69) | CRBNDDB1STAT3BRD4HDAC1 | |
| Trifluoroacetic Acid SCHEMBL29493524 | 0.88 | CRBN (0.65) | CRBNDDB1STAT3BRD4HDAC1 | |
| Trifluoroacetic Acid SCHEMBL17839640 | 0.88 | CRBN (0.65) | CRBNDDB1STAT3BRD4HDAC1 | |
| SCHEMBL20327270 | 0.87 | CRBN (0.59) | CRBNDDB1STAT3BRD4HDAC1 | |
| SCHEMBL20291289 | 0.87 | CRBN (0.73) | CRBNDDB1STAT3BRD4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| EP-3256470-B1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA FARBER CANCER INST INC (US) | 2023-07-26 | — | — | EP | disclosed |
| EP-4119552-A1 | REGULATING CHIMERIC ANTIGEN RECEPTORS | Dana-Farber Cancer Institute, Inc. (US) | 2023-01-18 | — | — | EP | disclosed |
| CN-108350062-B | Targeted protein degradation to attenuate adverse inflammatory responses associated with adoptive T cell therapy | 达纳-法伯癌症研究所股份有限公司 | 2022-10-14 | — | — | CN | disclosed |
| EP-3331905-B1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA FARBER CANCER INST INC (US) | 2022-10-05 | — | — | EP | disclosed |
| US-20220135967-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-11311609-B2 | Regulating chimeric antigen receptors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11293023-B2 | Tunable endogenous protein degradation | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20210301286-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-11059801-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3331905-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | Dana-Farber Cancer Institute, Inc. (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-3331906-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | Dana-Farber Cancer Institute, Inc. (US) | 2018-06-13 | — | — | EP | disclosed |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180009779-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| EP-3256470-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | Dana Farber Cancer Institute, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| WO-2017024317-A2 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017024319-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017024318-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017007612-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-01-12 | — | — | WO | disclosed |
| WO-2016105518-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210301286-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | NFATC1, GZMB, ICOS | CRBN 97/4885DDB1 940/4885STAT3 601/4885 |
| US-20180009779-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | CRBN 1/4885DDB1 113/4885STAT3 2989/4885 |
| US-11059801-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, XIAP, MDM2 | CRBN 1/4885DDB1 110/4885STAT3 3234/4885 |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | CRBN 158/4885DDB1 10/4885STAT3 2735/4885 |
| US-11293023-B2 | Tunable endogenous protein degradation | PSMG3, MYCBP, DBN1 | CRBN 138/4885DDB1 26/4885STAT3 2603/4885 |
| US-11311609-B2 | Regulating chimeric antigen receptors | NFATC1, TNFRSF9, IL2RA | CRBN 154/4885DDB1 979/4885STAT3 313/4885 |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | CRBN 1/4885DDB1 113/4885STAT3 2989/4885 |
| US-20220135967-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | PSMG3, MYCBP, DBN1 | CRBN 138/4885DDB1 26/4885STAT3 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.